Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 195.0 | 64 | |
| RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 280.0 | 72 | |
| RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 200.0 | 74 | |
| RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 174.0 | 78 | |
| RA2159 | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 175.0 | 74 | ||||
| N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 169.0 | 57 | |
| N2645 | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 158.5 | 64 | ||||
| RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 142.0 | 49 | |
| RA2708 | Poly(I:C) | 2 | ug/mL | 4 | IL12(p40) | 155.0 | 51 | ||||
| RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 207.0 | 69 | |
| RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 240.5 | 62 | |
| N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 264.0 | 57 | |
| N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 251.0 | 61 | |
| RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 290.5 | 68 | |
| RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 258.0 | 61 | |
| RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 201.0 | 55 | |
| RA2159 | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 179.0 | 50 | ||||
| N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 246.0 | 51 | |
| N2645 | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 238.0 | 63 | ||||
| RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 291.5 | 70 | |
| RA2708 | IL-1 alpha | 100 | ng/mL | 4 | IL12(p40) | 222.5 | 56 | ||||
| RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IL12(p40) | 189.0 | 56 | |
| RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IL12(p40) | 240.0 | 59 | |
| N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IL12(p40) | 202.0 | 66 | |
| N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IL12(p40) | 248.5 | 78 |